Ramping up its long-running interest in epigenetics, Boehringer Ingelheim GmbH (BI) has turned to Epizyme Inc. to help it inhibit undisclosed targets in two families of enzymes linked to the development of lung and other solid tumor cancers, helicase and histone acetyltransferase (HAT). The collaboration includes $20 million in near-term payouts for Epizyme plus up to $280.5 million in potential milestone payments and royalties. The targets are compelling not only because of "the clear role they play in cancer" but because both have patient stratification biomarkers, Boehringer said. Epizyme shares (NASDAQ:EPZM) rose 25 cents, or 3.4 percent, to $7.51 on Thursday.